iBio shares preclinical results showing IBIO‑610 preserves lean mass when combined with semaglutide
iBio Inc. released data from an eight‑week study in obese non‑human primates that compared semaglutide alone with a combination of semaglutide and the Activin E antibody IBIO‑610. The combination limited lean‑mass loss to 6% of total weight loss versus 22% with semaglutide alone, while fat accounted for 93% of the loss versus 77% in the control group. The antibody cut serum Activin E by 97% and exhibited a 33.2‑day half‑life, suggesting the possibility of twice‑yearly dosing in humans. The company said it will begin first‑in‑human Phase 1 trials in the first half of 2027.
Why it matters
The results indicate a potential differentiation for iBio’s obesity program by improving the quality of weight loss, which could make the therapy more attractive to patients and payors. If the projected half‑life holds in humans, the drug may require only two doses per year, reducing treatment burden and possibly enhancing market adoption.
Key facts
- 1The eight‑week study involved six obese non‑human primates per treatment group. investing.com
- 2Lean mass represented 6% of total weight loss with IBIO‑610 plus semaglutide, versus 22% with semaglutide alone. investing.com
- 3Fat accounted for 93% of weight loss in the combination group and 77% in the semaglutide‑only group. investing.com
- 4A single intravenous dose of IBIO‑610 reduced active Activin E levels by 97% at week eight. investing.com
- 5IBIO‑610 showed a 33.2‑day half‑life in non‑human primates. investing.com
- 6iBio plans to start first‑in‑human Phase 1 studies of IBIO‑610 in the first half of 2027. investing.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.